In a report released yesterday, Tara Bancroft from TD Cowen maintained a Buy rating on Sutro Biopharma (STRO – Research Report). The company’s shares closed yesterday at $3.27.
Bancroft covers the Healthcare sector, focusing on stocks such as MacroGenics, Fate Therapeutics, and Xencor. According to TipRanks, Bancroft has an average return of 38.4% and a 63.16% success rate on recommended stocks.
Currently, the analyst consensus on Sutro Biopharma is a Strong Buy with an average price target of $13.25.
STRO market cap is currently $208.5M and has a P/E ratio of -1.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sutro Biopharma (STRO) Company Description:
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
